| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/04/2006 | US7022709 Producing pharmaceuticals for improving perception, concentration, learning and/or memory. |
| 04/04/2006 | US7022707 such as S-4-[(2-propylamino)carbonyl]oxybenzyl piperazine-1-thiocarboxylate for treatment of obesity and/or diabetes |
| 04/04/2006 | US7022706 Central nervous system disorders |
| 04/04/2006 | US7022701 for treatment of disorders (sleeping, feeding) relating to or affected by the 5-HT6 receptor; serotonin receptor antagonists |
| 04/04/2006 | US7022699 Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| 04/04/2006 | US7022697 4-(Oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]-nonane derivatives, preparation and therapeutic use thereof |
| 04/04/2006 | US7022694 Indoles and indolines having 5-HT activity |
| 04/04/2006 | US7022691 Penicillinate compounds; bactericides for use against antibiotic resistant bacteria |
| 04/04/2006 | US7022690 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 04/04/2006 | US7022689 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor |
| 04/04/2006 | US7022678 Pregabalin lactose conjugates |
| 04/04/2006 | US7022676 obtained by hydrolysis of casein; hypotensive agentsl; for use in foods and drugs |
| 04/04/2006 | US7022672 Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor |
| 04/04/2006 | US7022521 Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents |
| 04/04/2006 | US7022315 Administering a thiol-based chemoprotectant agent intra-arterially for therapy and prophylaxis of side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck |
| 04/04/2006 | US7022312 Condensation aerosol as doage forms, is produced by heating a thin layer containing of dolasetron, granisetron or metoclopramide to form vapor, condense into an aerosol; fast producing peak plasma concentrations |
| 04/04/2006 | CA2379521C Methods to identify compounds that modulate rage |
| 04/04/2006 | CA2356544C Pyridotriazines and pyridopyridazines |
| 04/04/2006 | CA2354123C New benzothiadiazine derivatives, their preparation process and the pharmaceutical compositions that contain them |
| 04/04/2006 | CA2256492C Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
| 04/04/2006 | CA2241787C Substituted aza- and diazacycloheptane and cyclooctane compounds and their use |
| 04/04/2006 | CA2193039C Indol-2-one derivatives |
| 04/04/2006 | CA2166315C Process for the preparation of thalidomide |
| 04/04/2006 | CA2103022C Improvements in benzodiazepine treatment by cholinesterase inhibitors |
| 03/30/2006 | WO2006033949A1 Lactobacillus iners for reduction of human malodor |
| 03/30/2006 | WO2006033481A1 Soluble toll-like receptor 4 protein |
| 03/30/2006 | WO2006033422A1 Quinolizinone compound and use thereof as hiv integrase inhibitor |
| 03/30/2006 | WO2006033355A1 Oral pharmaceutical for dry skin prevention or remedy |
| 03/30/2006 | WO2006033287A1 PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND GLUTATHIONE |
| 03/30/2006 | WO2006032674A1 Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| 03/30/2006 | WO2003062369A3 Expansion of renewable stem cell populations |
| 03/30/2006 | WO2003014294A3 Tacis and br3 polypeptides and uses thereof |
| 03/30/2006 | US20060069264 Aza hydroxylated ethyl amine compounds |
| 03/30/2006 | US20060069246 Tumor necrosis factor receptor related proteins Tango-63d and Tango-63e |
| 03/30/2006 | US20060069242 Neurotrophic factor receptor |
| 03/30/2006 | US20060069148 Prostaglandins for prostaglandin mediated diseases such as antihistamines |
| 03/30/2006 | US20060069133 Administering a composition consisting of 2-ethoxy-1-[[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, a prodrug thereof or a salt thereof, a PPAR gamma agonist-like substance; diabetes, obesity |
| 03/30/2006 | US20060069131 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
| 03/30/2006 | US20060069130 Novel crystals |
| 03/30/2006 | US20060069129 Chemokine receptor binding heterocyclic compounds |
| 03/30/2006 | US20060069126 Pharmaceutically active isoindoline derivatives |
| 03/30/2006 | US20060069104 Neurotrophic factor production accelerator |
| 03/30/2006 | US20060069103 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 03/30/2006 | US20060069092 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 03/30/2006 | US20060069084 Methods of inhibiting kinases |
| 03/30/2006 | US20060069067 Combination of an aromatase inhibitor with a bisphosphonate |
| 03/30/2006 | US20060069037 Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors |
| 03/30/2006 | US20060069025 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068453 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068043 Aqueous solution of flavonoids and anthocyanins |
| 03/30/2006 | US20060068036 Extract of Dioscorea sp. and the medical uses thereof |
| 03/30/2006 | US20060068035 Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals |
| 03/30/2006 | US20060068027 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| 03/30/2006 | US20060068016 Paticulate product comprising pantethine |
| 03/30/2006 | US20060067947 Immunotherapeutic for cancer |
| 03/30/2006 | US20060067946 Method of treatment using ligand-immunogen conjugates |
| 03/30/2006 | US20060067932 Antagonists specific for denatured collagen and methods of using same |
| 03/30/2006 | US20060067921 Probiotic bacterium: lactobacillus fermentum |
| 03/30/2006 | US20060067910 Polyethylene glycol-polyglutamic acid block copolymer conjugates with e.g. 7-ethyl-10-hydroxycamptothecin or topotecan for sustained release; water solubility, anticancer agents |
| 03/30/2006 | US20060067885 ablating a targeted non-malignant B cell, comprising administering to a human subject having an immune disease an unconjugated monoclonal antibody (LL2 antibody) which binds to a marker that is specific for a B cell |
| 03/30/2006 | CA2580860A1 Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
| 03/30/2006 | CA2580845A1 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| 03/30/2006 | CA2580757A1 Orally administered agent for preventing or improving dry state of skin |
| 03/30/2006 | CA2580208A1 Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| 03/29/2006 | EP1640452A1 OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| 03/29/2006 | EP1640382A1 Anti-angiogenic peptides |
| 03/29/2006 | EP1640381A2 Neurotrophic growth factor |
| 03/29/2006 | EP1640369A1 Thiazolimine compound and oxazolimine compound |
| 03/29/2006 | EP1640366A1 Heterocyclic methyl sulfone derivative |
| 03/29/2006 | EP1640021A1 Preventive/remedy for urinary disturbance |
| 03/29/2006 | EP1640009A1 Estrogenic compounds as antimitotic agents |
| 03/29/2006 | EP1639994A2 Topical composition comprising N-acetylaldosamines or N-acetylamino acids |
| 03/29/2006 | EP1639902A1 Movement physiology improver |
| 03/29/2006 | EP1638919A1 Sphingolipids polyalkylamines conjugates |
| 03/29/2006 | EP1638611A1 Sphingolipids polyalkylamine conjugates for use in transfection |
| 03/29/2006 | EP1638610A1 Sphingoid polyalkylamine conjugates for vaccination |
| 03/29/2006 | EP1638605A2 Delivery of therapeutic compounds to the brain and other tissues |
| 03/29/2006 | EP1638591A1 Class iii slrp agonists for the reduction of blood vessel formation |
| 03/29/2006 | EP1638562A1 Use of tripolidine in providing refreshedness on waking |
| 03/29/2006 | EP1523311B1 Calcium lactate and whey permeate for lowering the triglyceride level |
| 03/29/2006 | EP1467998B1 Tetracyclic heterocompounds as estrogen receptor modulators |
| 03/29/2006 | EP1461083B1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 03/29/2006 | EP1414408B1 Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt |
| 03/29/2006 | EP1402270B1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 03/29/2006 | EP1395563B1 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
| 03/29/2006 | EP1385496A4 Use of compositions for treating rosacea |
| 03/29/2006 | EP1358354B1 Method for identifying compounds modulating reverse cholesterol transport |
| 03/29/2006 | EP1347765B1 Dermatological aqueous formulations containing clindamycin and a water soluble zinc salt |
| 03/29/2006 | EP1346039B1 Human cervical cancer 2 protooncogene and protein encoded therein |
| 03/29/2006 | EP1330453B1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 03/29/2006 | EP1320552B1 Method for producing human anti-thymocyte immunoglobulins |
| 03/29/2006 | EP1289552B1 Methods for treating hemostatic disorders by soluble p-selectin |
| 03/29/2006 | EP1226279B1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 03/29/2006 | EP1222266B1 Pca3 messenger rna in benign and malignant prostate tissues |
| 03/29/2006 | EP1200395B1 Urea derivatives as inhibitors of ccr-3 receptor |
| 03/29/2006 | EP1181376B1 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 03/29/2006 | EP1079847B1 Osteoporosis treatment |
| 03/29/2006 | EP1077715B1 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process |
| 03/29/2006 | EP0990031B1 Tumor necrosis factor receptor 5 |
| 03/29/2006 | EP0948541B1 Analogs of PTHrP |